News | Brachytherapy Systems | October 05, 2017

New Clinical Data Supports Xoft Brachytherapy System for Nonmelanoma Skin and Early-Stage Breast Cancer

Data presented at ASTRO 2017 show electronic brachytherapy offers painless, non-invasive option for several cancer types

October 5, 2017 — External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of nonmelanoma skin cancer (NMSC) and early-stage breast cancer during the 2017 American Society for Radiation Oncology (ASTRO) meeting, Sept. 24-27 in San Diego. iCAD also hosted additional presentations and a series of peer-to-peer discussion opportunities with leading eBx experts at its booth.

In an oral presentation, Rakesh Patel, M.D., radiation oncologist at Precision Cancer Specialists, reviewed results from a study published in the Journal of Contemporary Brachytherapy comparing the use of the Xoft System and Mohs micrographic surgery for the treatment of NMSC. 

“While Mohs surgery is considered the standard of care for NMSC, Xoft skin eBx represents an important option for many patients that can target the radiation dose directly to the cancerous site in a painless, non-invasive procedure,” said Patel. “We are excited to present these data, which add to a growing body of evidence indicating that eBx offers comparable results to Mohs surgery in appropriately selected early-stage NMSC patients.”

Nicholas Flores, M.D., director of radiation oncology at Arizona Dermatology, also presented data from a study of the treatment of peri-ocular NMSC using the Xoft System. From 2013 to 2016, Flores and fellow researchers treated 86 patients with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the eyelid with Xoft skin eBx. Results showed a 99 percent local control rate at two years post-treatment and no reported cases of side effects, such as long-term vision changes, dry eye, corneal injury, or retinitis.

Alam M. Nisar Syed, medical director, radiation oncology & endocurietherapy, MemorialCare Cancer Institute, Long Beach Memorial Medical Center, also presented data on the use of intraoperative radiation therapy (IORT) with the Xoft System in early-stage breast cancer patients. Syed discussed a non-randomized, prospective, multi-center trial that involved 1,076 patients with ductal carcinoma in situ (DCIS) or invasive ductal carcinoma who met specific selection criteria and received lumpectomy followed by IORT with the Xoft System. Results showed that Xoft IORT deliver low morbidity, excellent to good cosmetic results and a low rate of high-grade adverse events and recurrences in appropriate patients.

For more information: www.icadmed.com

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
breast screening
News | Clinical Trials | September 13, 2018
Fewer and fewer women die from breast cancer in recent years but, surprisingly, the decline is just as large in the a
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Feature | Breast Imaging | September 07, 2018 | By JoAnn Pushkin
If you are confused about the conflicting advice surrounding mammography screening guidelines, welcome to the club.
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...